Company / Cost of Revenue
Regeneron Pharmaceuticals Cost of Revenue History
FY2016-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$237.5M
FY2020
5-year range
-
FY2016-FY2020
Trend
-41.0%
vs FY2019
Sector context
#33 of 85
Health Care
What the data says
At $238M, Regeneron Pharmaceuticals's cost of revenue ranks #53 of 85 in the Health Care sector.
Based on SEC 10-K filings.
$238M in FY2020 with a 3-year CAGR of +5.5%.
Remained stable around $238M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +5.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#53 of 85 in Health CareTop 61% of 85This company $237.5M Sector average $2.0B
▼
-88.0% below sector average
Key checks
Key Insights
- 3-year CAGR of +5.5%, indicating consistent growth.
- In FY2020, cost of revenue decreased 41.0% year-over-year.
- Ranks #33 out of 85 companies in the Health Care sector.
- Peak cost of revenue was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score 3.03 (safe zone, above 2.9 threshold)
- Strong profit margin: 32.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | $237.5M | -41.0% |
| FY2019 | $402.8M | +69.6% |
| FY2018 | $237.5M | +17.3% |
| FY2017 | $202.5M | +4.1% |
| FY2016 | $194.6M | -19.5% |
As of FY2020 · SEC 10-K · Updated Jun 30, 2026